Join
Login
Join
Login
"Where Everyone Has an MBA"
Tel: (612) 246-4616
Home
Financial Analysis
Companies
Industries
Glossary
About
Frequently Asked Questions
User Testimonials
Contact Us
Navigation
Home
Financial Analysis
Companies
Industries
Glossary
About
- Frequently Asked Questions
- User Testimonials
Contact Us
Bone Biologics Corp - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS
Ticker
Exchange
SIC #
Website
Latest Ticker
BBLG
Nasdaq
3841
https://www.bonebiologics.com/
Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:
Latest Headlines for Bone Biologics Corp
Bone Biologics Effects 1-for-30 Reverse Stock Split
- Jun 6th, 2023 5:00 pm
BBLG: BBLG Has Solid Cash and Is Advancing Testing
- May 16th, 2023 11:20 am
BBLG: Bone Biologics Announces the Approval of A Vital Trial
- Apr 11th, 2023 12:27 pm
Bone Biologics Receives Human Research Ethics Committee Approval to Begin Pilot Clinical Trial with NB1 in Spinal Fusion Patients in Australia
- Apr 11th, 2023 12:00 pm
BBLG: BBLG Provides Investment Opportunity Before Trials
- Mar 17th, 2023 10:29 am
Bone Biologics Advances Preparations for NB1 Pilot Clinical Trial with Engagement of Contract Research Organization
- Jan 26th, 2023 1:30 pm
BBLG: A Potential Game-Changer for Back Surgeries
- Nov 15th, 2022 11:10 am
Bone Biologics CEO Issues Letter to Stockholders
- Oct 25th, 2022 12:00 pm
WallachBeth Capital Announces Closing of Bone Biologics $5,100,000 Underwritten Public Offering
- Oct 13th, 2022 1:00 pm
Bone Biologics Announces Closing of $5,100,000 Underwritten Public Offering
- Oct 12th, 2022 8:05 pm
CORRECTING and REPLACING Bone Biologics Prices $5,100,000 Underwritten Public Offering
- Oct 7th, 2022 2:52 pm
WallachBeth Capital Announces Pricing of Bone Biologics $5,100,000 Underwritten Public Offering
- Oct 7th, 2022 2:16 pm
BBLG: Market opportunity for Bone continues to grow.
- Sep 15th, 2022 10:20 am
BBLG: Bone Biologics Set up For Success
- Jun 7th, 2022 11:23 am
Scroll